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Abstract: The importance of assessing the probability of venous 
thromboembolism recurrence, a condition that includes deep vein thrombosis 
and pulmonary embolism, lies in the fact that it is the most important factor in 
deciding the duration of anticoagulant treatment. Risk of recurrence depends 
mostly on the presence of a risk factor for developing venous thromboembolism, 
with patients with unprovoked events being at the higher risk of recurrence. The 
risk of recurrence needs to be balanced with the risk of bleeding and the potential 
severity of these thrombotic and hemorrhagic events. 
 
In patients with an unprovoked venous thromboembolism who complete 
treatment for the acute (first 10 days) and post-acute phase of the disease (from 
day 10 to 3-6 months), decision has to be made regarding prolonged 
antithrombotic therapy to prevent recurrences. The main goal of extended 
treatment is preventing recurrences with a safe profile in terms of bleeding risk. 
Many therapeutic options are now available for these patients, including 
antiplatelet therapy with aspirin or direct oral anticoagulants. Moreover, 
apixaban and rivaroxaban at prophylactic doses have demonstrated efficacy in 
preventing recurrences with a low risk of bleeding. 
 
 
Keywords: anticoagulation; venous thromboembolism; bleeding. 
 
 
Key Messages:  
• Extending treatment (longer than 3 to 6 months) are challenging in patients 
with Venous Thromboembolism (VTE) and depend on the risk of venous 
thromboembolism recurrence, the bleeding risk and patient and physician 
preferences. 
• Anticoagulation treatment should be stopped in patients with provoked VTE 
and in those with unprovoked VTE and a high bleeding risk after initial period of 3 
to 6 months.  
• There are some therapeutic alternatives (including Aspirin and low dose of 
some NOACs) to reduce venous thromboembolism recurrence risk in patients 
with unprovoked VTE and a low bleeding risk for extended treatment of VTE (after 
initial period of 3 to 6 months)  
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1. Introduction 
Venous Thromboembolism (VTE) includes deep-vein thrombosis (DVT) and 
pulmonary embolism (PE), and represents the third cause of vascular disease-
related deaths. The mainstay of treatment is anticoagulation, and current 
guidelines recommend to treat patients for 3 months or longer1,2. Decisions about 
extending treatment (longer than 3 to 6 months) are challenging and depend on 
the risk of venous thromboembolism recurrence once anticoagulation is stopped. 
It has been estimated in about 10% within the first year and 30% in the first five 
years in patients without reversible risk factors3.  
When considering extended anticoagulant therapy, a balance should be 
performed including the risk of VTE recurrence, the bleeding risk and patient and 
physician preferences. Vitamin K antagonist (VKA) therapy, as well as Non-vitamin 
K antagonist oral anticoagulants (NOACs) and aspirin, are effective for the 
prevention of VTE recurrence, but the inconvenience of laboratory monitoring in 
the case of VKA therapy and concerns about bleeding lead to reluctance to 
continue anticoagulation beyond the first 3-6 months. Aim of this review is to 
report the available evidences regarding the extended treatment for venous 
thromboembolism. 
2. Evaluation of the risk of VTE recurrence 
Calculating the likelihood of VTE recurrence is the most important factor to guide 
anticoagulant treatment duration. In this regard, it is important to classify the 
thrombotic event in unprovoked (formerly called idiopathic) or provoked.  
An episode of VTE is considered unprovoked when a major trigger, usually 
environmental or acquired (such as surgery or immobilization) is not identified. 
However, this definition is not standardized, since there are minor or transient 
risk factors (RFs), such as hormonal treatment or minor thrombophilia, in which 
the associated VTE events are considered unprovoked or provoked according to 
different studies4-7.  
In this sense, a standardization of the terms has recently been proposed with the 
aim of improving clinical practice and research4. According to this proposal, the 
term 'unprovoked' rather than 'idiopathic' defines an episode of VTE in which 
there is no previous identifiable RFs while an episode is considered 'provoked' 
when it is preceded by a transient major, minor or persistent RF. Major RFs 
appear 3 months prior to the event; are associated with 50% less recurrence after 
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anticoagulation withdrawal in comparison with unprovoked events and increase 
the risk of a first episode of VTE more than 10 times. Examples of major RFs are 
major surgery or prolonged immobilization. Minor RFs appear in the 2 months 
previous to the episode of VTE and are associated with a 50% less recurrence 
after anticoagulation withdrawal in comparison with unprovoked events and 
increase the risk of a first episode from 3 to 10 times. An example of minor RFs is 
treatment with estrogens. Finally, persistent RFs would be active cancer, or those 
conditions that multiply at least 2 times the risk of VTE recurrence after 
anticoagulation withdrawal4. Figure 1. 
VTE recurrence rate after treatment discontinuation for unprovoked events is as 
high as 10% after the first year reaching 30% after 5 years5-7. This recurrence rate 
is lower for provoked events caused by surgery (3% at 5 years) or a non-surgical 
RF (15% at 5 years)5. Patients with higher recurrence rate must be identified and 
separated from those with a single provoked VTE, in which the extension of 
anticoagulant treatment to more than 3-6 months is not necessary. The 
recurrence risk after anticoagulant discontinuation in unprovoked VTE does not 
vary depending on the duration of the anticoagulant treatment8,9. 
There are some additional factors that condition the risk of recurrence after a first 
episode of unprovoked VTE, which can help in the decision whether to prolong 
anticoagulant therapy after the initial period of 3-6 months, together with the 
estimation of the bleeding risk10. First, the previous history of VTE must be 
highlighted, since a previous episode of unprovoked VTE increases the risk of 
recurrence in 45% within 5 years5. Another factor would be older (or increasing) 
age, which multiplies by 1.7 the recurrence risk per each decade of life; male sex 
has an increased relative risk of 1.3-3.6 higher than females11. Obesity and post-
thrombotic syndrome multiply recurrence risk by 2.612,13. The index event has not 
shown to be a risk predictor, except in the case of distal DVT, which shows 51% 
less risk of recurrence when compared to proximal DVT14. Minor thrombophilias 
(heterozygosis for factor V Leiden and prothrombin G20210A) confer a minimal 
increase in relative risk of 1.4-1.7 so their presence should not condition 
treatment duration15, while major thrombophilias (antithrombin III, C and S 
deficiencies) and antiphospholipid syndrome involve high recurrence risk and its 
presence might require indefinite anticoagulation. Residual venous thrombosis 
alone without post-thrombotic syndrome is not useful in predicting VTE 
recurrence16.  
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D-dimer determination is perhaps the most useful laboratory test to predict 
recurrence but is not definitive. High concentrations of D-dimer one month after 
stopping anticoagulant treatment is associated with an increased risk of recurrent 
VTE17,18. Nevertheless, a normal concentration is not able to identify patients with 
low risk19. The combined use of D-dimer with other predictors, such as residual 
venous thrombosis (D-dimer and Ultrasonography in Combination Italian Study 
[DULCIS])17 or the gender, has greater prediction ability than D-dimer alone. In 
fact, male gender and D-dimer are the risk predictors present in the 3 scales for 
prediction of VTE recurrence (D-dimer, Age, Sex male, Hormonal Therapy [DASH], 
Vienna Scale, and Hyperpigmentation, Edema or Redness, D-dimer, Obesity, Older 
age [HERDOO2]), which may be helpful, but only the HERDOO2 scale has been 
validated to guide treatment duration for women with unprovoked VTE20, while 
for the other two models external validation is still needed11. 
3. Bleeding Risk Evaluation 
The main limitation of long-term anticoagulation is bleeding risk, which is 
estimated globally in 2.06-2.24% (0.2-0.55% of fatal bleeding), which implies a 
mortality rate of 9.3-20.2% during the first 3 months21-24. After this period the risk 
of bleeding is 2.74 % per year, with a mortality rate of 2-18.2%21-24. The bleeding 
risk should be compared with the rate of fatal events due to recurrent VTE, which 
is estimated in 0.4% within the first 3 months, with a mortality rate of 11.3-16.1% 
(greater in pulmonary embolism than in DVT) and of 0.3% patients/year, being 
the mortality rate 2-3.6% after that time21-24 . In the light of these data, it appears 
clear that the incidence and mortality of recurrent VTE seems to decrease over 
time while bleeding risk remains stable, therefore after the initial treatment 
period bleeding risk evaluation becomes as important as the recurrence one. 
For the estimation of the bleeding risk, the American College of Chest Physicians 
(ACCP) used a model based on the number of predisposing bleeding factors in 
each patient, which can range from 1.6% to 12.8% in the first 3 months of 
anticoagulation and within 0.8% and more than 6.5% per year, after that period2. 
The only validated scale to evaluate the short-term (3 months) bleeding risk is 
RIETE (Registro Informatizado de Enfermedad Tromboembólica) score, a risk 
score based on six variables (age >75 years, recent bleeding, cancer, creatinine 
levels >1.2 mg/dl, anemia, or pulmonary embolism at baseline) that can identify 
VTE patients at low, intermediate, or high risk for major bleeding during the first 
three months of therapy25. There are no risk estimation scales for long-term 
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bleeding risk validated in patients with VTE, in opposition to the case of atrial 
fibrillation.  
4. New therapeutic Options in Extended Treatment for VTE 
The main available therapeutic options for extended treatment for VTE patients 
have been summarized in Figure 2. 
As previously discussed, depending on the balance between individual VTE 
recurrence risk after discontinuation of anticoagulation and the bleeding risk 
while receiving treatment, prolonging anticoagulation into a secondary 
prevention (extended phase) may be justified after the initial treatment of acute 
and post-acute phase (3-6 months) for VTE.  
The level of adherence to treatment guidelines for long-term management of VTE 
in the outpatient setting is unclear26. Factors that might limit the acceptance of 
extended anticoagulation include the current requirement for therapeutic 
monitoring and dietary restrictions with VKA, along with patients and clinicians 
perception of the bleeding risk associated with VKA anticoagulation27.  
More convenient anticoagulant agents with at least equivalent efficacy and safety 
may lead to more widespread acceptance of extended anticoagulation. Various 
strategies have been studied to reduce the cost, complexity, and toxicity of long-
term anticoagulation therapy. Reduced-intensity warfarin proved to be less 
effective than standard intensity warfarin in randomized, controlled trials28,29. 
Other studies have evaluated different antithrombotic strategies in extended 
treatment and will be summarized in the following paragraphs. 
Aspirin. The use of aspirin in the prevention of VTE recurrence was evaluated in 
two randomized clinical trials.  The first one was the WARFASA trial30, a 
multicenter, double-blinded trial that included patients with unprovoked VTE who 
had completed previously 6 to 8 months of treatment with oral anticoagulants. 
These patients were randomized to receive aspirin 100 mg per day vs placebo, 
during 2 years. VTE recurred in 28 of the 205 patients who received aspirin and in 
43 of the 197 patients who received placebo (6.6% vs. 11.2% per year; HR 0.58; 
95% confidence interval [CI], 0.36 to 0.93; p=0.02). The obtained outcomes 
showed that aspirin therapy reduced the rate of recurrence of VTE by about 40% 
compared to placebo, which suggests that it could be an interesting alternative to 
extended oral anticoagulant treatment for the prevention of VTE recurrences, 
with no increased risk for major bleeding or other adverse events compared to 
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placebo; some limitations should be considered regarding the bleeding risk (may 
be greater in real-world patients).  
A second study was the ASPIRE trial31 that included patients with a first episode of 
unprovoked VTE who had completed initial treatment with oral anticoagulants. 
They randomly assigned 411 patients to treatment with aspirin 100 mg a day and 
411 patients to placebo for up to 4 years. VTE recurred in 73 of 411 patients 
assigned to placebo and in 57 of 411 assigned to aspirin (6.5% per year vs. 4.8% 
per year; HR with aspirin, 0.74; 95% confidence interval [CI], 0.52 to 1.05; p=0.09). 
showing that aspirin, as compared with placebo, did not significantly reduce the 
rate of recurrence of VTE, but it showed a significant reduction of 34% in the rate 
of major vascular events, with improved net clinical benefit and without 
increasing bleeding (rate of 0.6% per year with placebo vs. 1.1% per year with 
aspirin, p=0.22).  It seems that patients who have had a first unprovoked event of 
VTE have an increased risk of arterial thrombosis and cardiovascular death. 
Aspirin has demonstrated to reduce the rate of these events, including stroke, 
myocardial infarction and cardiovascular death. As a limitation there were fewer 
recruited patients than initially planned. In contrast, the combined results of 
ASPIRE and WARFASA trials showed a highly significant reduction of 32% in the 
rate of VTE recurrence31, providing significant evidence for the use of low dose 
aspirin therapy in the prevention of recurrent VTE and major vascular events in 
patients who have had a first episode of unprovoked VTE, considering aspirin as 
an alternative to anticoagulant treatment in the extended treatment of VTE. 
Dabigatran. Dabigatran, a NOAC that is a direct thrombin inhibitor. It was 
evaluated for the secondary prevention of VTE in the RE-SONATE and RE-MEDY 
trials32. These double-blinded randomized trials compared dabigatran at a dose of 
150 mg twice daily with warfarin (active-control study) or with placebo (placebo-
control study) in patients with venous thromboembolism who had completed at 
least 3 initial months of therapy.  
In the RE-MEDY trial (the active-control study) recurrent venous 
thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) 
and 18 of 1426 patients in the warfarin group (1.3%) (HR with dabigatran, 1.44; 
95% confidence interval [CI], 0.78 to 2.64; p=0.01 for non-inferiority), 
demonstrating that dabigatran 150 mg bid was non-inferior to warfarin in 
preventing VTE recurrence after 3–12 months of anticoagulant therapy. There 
was a significant reduction in major or non-major clinically relevant bleeding 
events with dabigatran compared with warfarin (HR 0.54; 95% CI, 0.41 to 0.71) 
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and an increase of major or clinically relevant bleeding when compared to 
placebo group (HR 2.92; 95% CI, 1.52 to 5.60; p<0.001). A higher incidence of 
acute coronary syndrome events was reported in patients receiving dabigatran in 
this study (0.9% vs 0.2% for warfarin; p = 0.02). A Limitation in trial design was 
reported due to the prespecified noninferiority margin for the hazard ratio that 
allowed an increase in risk by a factor of nearly 3 to be accepted as noninferior. 
The RE-SONATE trial randomized 1,343 patients to dabigatran 150 mg (681 
patients) or placebo (662 patients) for six months with extended follow-up to 
evaluate the long-term risk of recurrence (12 months after completion of study 
treatment) showing a 92 percent risk reduction for recurrent or fatal VTE with 
dabigatran versus placebo (three patients, 0.4 percent versus 37 patients, 5.6 
percent; p<0.001 for superiority) with a higher rate of major or clinically relevant 
bleeding in the dabigatran group versus no treatment (36 patients, 5.3 percent 
versus 12 patients, 1.8 percent; p=0.001) 
Apixaban. Apixaban is another NOAC, whose mechanism of action is the 
inhibition of factor Xa. The AMPLIFY-EXT trial33 compared apixaban at 2 different 
doses (2.5 mg or 5 mg bid) for 12 months with placebo for secondary prevention 
of VTE after 6–12 months of initial anticoagulant treatment. Investigators selected 
both dosis on the basis that apixaban at 5 mg twice daily has been shown to be 
effective for  the prevention of stroke in patients with atrial fibrillation, and at a 
dose of 2.5 mg twice daily, it has been shown to be effective for 
thromboprophylaxis after major orthopedic surgery.34,35 
This randomized, double-blind study that included 2482 patients, showed that 
extended anticoagulation with apixaban at both doses reduced the risk of 
recurrent VTE without increasing the rate of bleeding. Concerning the recurrence 
of VTE or VTE-related death, it occurred in 73 of 829 patients (8.8%) receiving 
placebo, 14 of 840 patients (1.7%) receiving 2.5 mg of apixaban (reduction of 
7.2%; 95% CI, 5.0 to 9.3; p<0.001); and 14 of 813 patients (1.7%) receiving 5 mg of 
apixaban (reduction of 7%; 95% CI, 4.9 to 9.1; p<0.001). The rates of major 
bleeding were similar for apixaban compared with placebo (2.5 mg group vs 
placebo: 0.2% vs 0.5%; RR 0.49; 95% CI 0.09–2.64; 5 mg group vs placebo: 0.1% vs 
0.5%; RR 0.25; 95% CI 0.03–2.24). The rate of death from any cause was 1.7% in 
the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 
0.5% in the 5-mg apixaban group, making AMPLIFY-EXT trial the first study of 
Ac
ce
pte
d M
nu
scr
ipt
secondary prevention of TVE that showed anticoagulant therapy to reduce the 
risk of all-cause mortality.  
Edoxaban. Edoxaban is another NOAC approved for the treatment of VTE whose 
mechanism of action is the inhibition of factor Xa. The HOKUSAI-VTE study36 (a 
randomized, double-blind, double-dummy trial designed to assess the efficacy 
and safety of edoxaban for the treatment of VTE), showed that a single daily dose 
of edoxaban was as effective and safer than warfarin after an initial course of 
heparin for 5 days (acute phase) in patients with VTE, but the decision to prolong 
treatment duration beyond 3 months (extended phase) and up to 12 months in 
the trial, was decided based on investigators discretion, to simulate clinical 
practice. The trial was not specifically designed to address edoxaban compared to 
warfarin or aspirin for the extended treatment of VTE. This limits the available 
data regarding edoxaban in this setting. However, a post-hoc analysis of 
HOKUSAI-VTE study37, compared edoxaban with warfarin in those patients who 
continued therapy beyond 3 months and completed treatment for 12 months 
(40% of initially recruited patients); the incidence rate of recurrent VTE were 1.8% 
in the edoxaban group and 1.9% in the warfarin group (HR 0.97; 95% CI 0.69–
1.37) and regarding major bleeding were 0.3% and 0.7%, respectively (HR 0.45; 
95% CI 0.22–0.92). This provides additional data that edoxaban could be a safe 
alternative to warfarin for extended treatment in VTE. 
Rivaroxaban. Rivaroxaban is another NOAC that acts by inhibiting factor Xa as 
well. The EINSTEIN EXT study38 evaluated rivaroxaban for secondary VTE 
prevention after initial anticoagulant treatment for 6–12 months. Rivaroxaban 
20 mg for an additional 6 or 12 months was associated with a significant 82% 
reduction in the relative risk of VTE recurrence compared with placebo, without a 
significantly increased risk of major bleeding,. A net clinical benefit, defined as the 
composite of the primary efficacy outcome or major bleeding, was observed with 
rivaroxaban compared with placebo (2.0% vs 7.1%, p < 0.001).  
More recently, results from EINSTEIN CHOICE study39 were published. In this 
randomized, double-blinded, phase 3 study, 3396 patients with venous 
thromboembolism were assigned to receive either once-daily rivaroxaban (at 
doses of 20 mg or 10 mg) or 100 mg of aspirin. All patients had completed 6 to 12 
months of anticoagulation and duration of treatment was up to 12 months. 
Symptomatic recurrent fatal or nonfatal venous thromboembolism or 
unexplained death occurred in 17 of the 1107 patients (1.5%) assigned to receive 
20 mg of rivaroxaban, in 13 of 1127 (1.2%) assigned to receive 10 mg of 
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rivaroxaban, and in 50 of 1131 (4.4%) assigned to receive aspirin (HR for 20 mg of 
rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; HR for 10 
mg of rivaroxaban vs. Aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both 
comparisons). Major or clinically relevant nonmajor bleeding occurred in 3.3%, 
2.4%, and 2.0% of the patients, respectively, with no differences between the 3 
treatment groups. As limitation patients who required extended treatment with 
therapeutic doses of anticoagulant agents were excluded, therefore, it remains 
unknown whether the 10-mg dose of rivaroxaban would be sufficient to prevent 
recurrence in such patients. In summary, among patients with VTE the risk of a 
recurrent event was significantly lower with rivaroxaban at either a treatment 
dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a 
significant increase in bleeding rates.  
Thus, all direct oral anticoagulants evaluated for the secondary prevention of 
recurrent VTE appear to be effective agents for this indication, without an 
increased risk of bleeding compared to placebo (rivaroxaban and apixaban), lower 
bleeding risk than warfarin (dabigatran), lower major bleeding risk than warfarin 
(edoxaban), and similar bleeding risk than aspirin (rivaroxaban). The choice of 
agent is likely to be influenced by availability and individual patient characteristics 
or preferences. Extended treatment duration using NOACs (dabigatran, apixaban, 
edoxaban or rivaroxaban) for unprovoked VTE in clinical trials is up to 12 months 
and up to 4 years in the case of aspirin (ASPIRE Trial)31. After that period, a risk 
stratification should be performed at least annually to evaluate the risk of VTE 
recurrence and bleeding, and patient preference should also be adressed, in order 
to decide whether antithrombotic therapy should be continued. 
5. Extended Treatment in Cancer-Associated Thrombosis 
Several trials40-44, have been conducted in patients with cancer for the treatment 
of cancer-associated thrombosis (CAT); these trials reported statistically 
significant reduction in VTE recurrence with LMWH when compared with heparin 
followed by VKA, without increased bleeding, for at least a 3 to 6-month 
treatment period (acute and postacute phase) and this data is summarized in 
previous guidelines for CAT treatment45. Because the burdensome of daily 
subcutaneous injections with LMWH and the absence of known benefit beyond 6 
months, recently two clinical trials (HOKUSAI VTE Cancer and SELECT-D) 
comparing NOACs vs LMWH in extended treatment for CAT were performed46,47. 
The HOKUSAI VTE Cancer is a randomized, open-label, with a noninferiority design 
trial that compared oral edoxaban (60 mg once daily) or subcutaneous dalteparin, 
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given for at least 6 months and up to 12 months. The primary-outcome (a 
composite of recurrent VTE or major bleeding) occurred in 67 of the 522 patients 
(12.8%) in the edoxaban group and 71 of the 524 patients (13.5%) in the 
dalteparin group (HR of 0.97; 95% CI, 0.70 to 1.36; P=0.006 for noninferiority). 
Recurrent VTE occurred in 7.9% in the edoxaban group and in 11.3% in the 
dalteparin group (difference in risk, −3.4 percentage points; 95% CI, −7.0 to 0.2) 
but major bleeding occurred in 6.9% in the edoxaban group and in 4.0% in the 
dalteparin group (difference in risk, 2.9 percentage points; 95% CI, 0.1 to 5.6). 
Concluding that oral edoxaban was noninferior to subcutaneous dalteparin with 
respect to the composite outcome (recurrent venous thromboembolism or major 
bleeding), but the rate of major bleeding was higher with edoxaban than with 
LMWH46.  
Rivaroxaban at a dose of 15 mg twice daily for 3 weeks, then 20 mg once daily 
compared to dalteparin was evaluated in patients with CAT in the SELECT-D trial 
(randomized, multicenter and open-label). In this trial rivaroxaban was associated 
with relatively low VTE recurrence but higher major and clinically relevant 
nonmajor bleeding compared with LMWH, but the trial was designed to evaluate 
VTE recurrence over 6 months, limiting data on extendet treatment for CAT 
(longer than 6 months)47.  
A recent meta-analysis48 concluded that NOACs (edoxaban and rivaroxaban) were 
more effective than LMWHs to prevent recurrent VTE but also were associated 
with a small but significantly increased risk of major bleeding, especially in the 
subgroup of patients with gastrointestinal cancer. 
Thus, the optimal duration of anticoagulant therapy in patients with CAT is 
unknown, since evidence-based recommendations are lacking. Consensus 
guidelines generally suggest continuing anticoagulation treatment in patients with 
active cancer or receiving cancer treatment, with periodic reassessment of the 
risks and benefits45,49. LMWH continues to be the cornerstone of treatment in 
these patients, but NOACs (edoxaban and rivaroxaban) are also presented as an 
option to be considered in selected cancer patients. 
6. Conclusion 
Given the high rate of recurrence after an episode of unprovoked VTE, it is 
mandatory to individually balance the risk of bleeding and the risk of recurrence 
in these patients. In general terms, after a minimum period of 3-6 months 
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anticoagulant therapy should be stopped in patients with provoked VTE and those 
with unprovoked VTE and a high risk of bleeding. If bleeding risk is low or 
moderate, extended anticoagulation (over 6 months) should be considered. In 
selected cases, where the probability of recurrence is low due to the absence of 
additional risk factors (first episode of VTE, female sex, low D-dimer levels, 
absence of post-thrombotic syndrome, etc), and always after consulting the 
preferences of the patient, it may be appropriate to discontinue anticoagulation. 
Finally, in those patients with unprovoked VTE in whom anticoagulation is 
discontinued, aspirin reduces the risk of VTE recurrence (compared with placebo) 
although recurrence rates remain substantial; prophylactic doses of NOACs have 
some benefits (they do not require routine laboratory monitoring or dose 
adjustment and have fewer interactions with other drugs or food compared to 
warfarin) and are associated with a lower risk of most forms of bleeding with a 
significantly lower reduction in recurrent VTE when compared to aspirin 
(rivaroxaban) or placebo (rivaroxaban, apixaban). 
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Figures: 
Figure 1.     Venous thromboembolism according to different risk factors.  
 
Figure 2.     Duration of VTE therapy and therapeutic options. VTE: venous 
thromboembolism. RFs: risk factor DVT: Deep Vein Thrombosis. LMWH: low 
molecular weight heparin. 
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